Adherence to infliximab treatment in patients with immune-mediated inflammatory diseases from a referral center in Brazil: a cohort study
Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients t...
Saved in:
| Published in: | BMC gastroenterology Vol. 24; no. 1; pp. 384 - 13 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
29-10-2024
BioMed Central BMC |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital.
This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent.
The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center.
Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. |
|---|---|
| AbstractList | Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital. This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent. The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center. Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital. This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent. The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center. Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. BackgroundInfliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital.MethodThis ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent.ResultsThe treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center.ConclusionsDespite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital.BACKGROUNDInfliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital.This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent.METHODThis ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent.The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center.RESULTSThe treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center.Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate.CONCLUSIONSDespite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. Abstract Background Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital. Method This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent. Results The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center. Conclusions Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. Background Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence is essential to achieve the therapeutic objective. This study aimed to determine the rate of adherence to infliximab treatment in patients treated at a referral center at a university hospital. Method This ambispective cohort study included patients treated at the Professor Edgard Santos University Hospital (HUPES) referral center of our university hospital between March 2022 and February 2023. Sociodemographic, clinical, and pharmacotherapeutic data were collected from 101 patients through interviews and medical record reviews using a structured form. The adherence rate was defined as the proportion of days covered in a year. Patients who achieved an adherence rate > 80% were considered adherent. Results The treatment adherence rate was 91.04%. Individuals with inflammatory bowel diseases had a 39.1% higher risk of non-adherence to treatment compared with other patients in our sample (p < 0,05). Most patients achieved remission or control of the underlying disease activity and had good functional capacities. The main reason for absence on the scheduled date was difficulty traveling to the referral center. Conclusions Despite the reported difficulties, treatment adherence was observed to be high. As the study was conducted in a reference unit with multidisciplinary care and continuous monitoring for treatment effectiveness, safety, and adherence, welcoming and good communication between professionals and patients may have contributed to the high adherence rate. Keywords: Adherence, Infliximab, Immune-mediated inflammatory diseases |
| ArticleNumber | 384 |
| Audience | Academic |
| Author | Brauer, Alline Mikaelle Nunes Wildemberg de Araújo Costa Beisl Noblat, Lucia Oliveira, Livia Brito Santana, Genoile Oliveira Pereira, Fernanda Silva Lauton, Priscila Moreira Santos, Pablo Moura |
| Author_xml | – sequence: 1 givenname: Priscila Moreira surname: Lauton fullname: Lauton, Priscila Moreira organization: Programa de Pós-Graduação em Assistência Farmacêutica em Rede e Associação de Instituições de Ensino Superior, Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Brasil – sequence: 2 givenname: Fernanda Silva surname: Pereira fullname: Pereira, Fernanda Silva organization: Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Brasil – sequence: 3 givenname: Livia Brito surname: Oliveira fullname: Oliveira, Livia Brito organization: Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brasil – sequence: 4 givenname: Alline Mikaelle Nunes Wildemberg surname: Brauer fullname: Brauer, Alline Mikaelle Nunes Wildemberg organization: Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brasil – sequence: 5 givenname: Lucia surname: de Araújo Costa Beisl Noblat fullname: de Araújo Costa Beisl Noblat, Lucia organization: Programa de Pós-Graduação em Assistência Farmacêutica em Rede e Associação de Instituições de Ensino Superior, Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Brasil – sequence: 6 givenname: Genoile Oliveira surname: Santana fullname: Santana, Genoile Oliveira organization: Departamento de Ciências da Vida, Universidade do Estado da Bahia (UNEB), Salvador, Brasil – sequence: 7 givenname: Pablo Moura surname: Santos fullname: Santos, Pablo Moura email: pablomoura@ufba.br, pablomoura@ufba.br organization: Programa de Pós-Graduação em Assistência Farmacêutica em Rede e Associação de Instituições de Ensino Superior, Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Brasil. pablomoura@ufba.br |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39472788$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUk1v1DAQjVARbRf-AAdkiQuXlIydOF4uaKn4qFSJSw_cLCee7HqVxIvtdCn_gH_N7G4pXYQsy6Pxe89643eenYx-xCx7CcUFgJJvI3BVy7zgZV6Isqry7ZPsDMoaci6KbyeP6tPsPMZ1UUCtuHiWnYp5WfNaqbPs18KuMODYIkueubHr3Q83mIalgCYNOCZqso1JjsrIti6tmBuGacR8QOtMQrtnmWEwyYc7Zl1EEzGyLviBGRawwxBMz1oSwLBT-xDMT9e_o8vWr3xILKbJ3j3Pnnamj_ji_pxlN58-3lx-ya-_fr66XFznrZhLyOddpzposYSusqJrbG3qpuBWQKNKPheqaWlDXfIKKgWWC4FSdoVFa7g0YpZdHWStN2u9CWQ23GlvnN43fFhqE5Jre9RmbgErLokry0LhHCRwawWvrISahGfZ-4PWZmpoGjuH5PRI9PhmdCu99LcaoOJCgSSFN_cKwX-fMCY9uNhi35sR_RS1AM6lKEWhCPr6H-jaT2GkUe1QsgQhufyLWhpyQD_j6eF2J6oXCkpQXHJOqIv_oGhZHFxLKesc9Y8I_EBog4-R_vTBJBR6F0Z9CKOmMOp9GPWWSK8ej-eB8id94jfKIN0r |
| Cites_doi | 10.1097/MIB.0b013e31828132cb 10.1093/ibd/izy102 10.1111/1751-2980.12539 10.1016/j.sapharm.2020.10.011 10.3389/fphar.2023.1185026 10.1093/ecco-jcc/jjv096 10.5217/ir.2017.15.4.434 10.1016/j.rbr.2016.05.003 10.1056/NEJMra1909094 10.1016/j.clinthera.2011.06.001 10.18549/PharmPract.2021.2.2312 10.3390/ijms22052719 10.1097/MIB.0000000000001043 10.3899/jrheum.140538 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QP 7QR 7T5 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH H94 K9. M0S M1P P64 PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12876-024-03455-w |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biotechnology and BioEngineering Abstracts Publicly Available Content (ProQuest) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database Technology Research Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-230X |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_a9d1e5260de6408e91612dd325d61723 A814182622 10_1186_s12876_024_03455_w 39472788 |
| Genre | Journal Article |
| GeographicLocations | Brazil |
| GeographicLocations_xml | – name: Brazil |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M~E NPM O5R O5S OK1 P2P PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION 7QP 7QR 7T5 7XB 8FD 8FK AZQEC DWQXO FR3 H94 K9. M48 P64 PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c3961-9ff8f1ce41f5d3fbd7a7b02d31b842938bc38b174251581d233e66f0deda26a3 |
| IEDL.DBID | RPM |
| ISSN | 1471-230X |
| IngestDate | Mon Nov 04 19:56:59 EST 2024 Thu Oct 31 05:28:52 EDT 2024 Fri Nov 01 20:49:08 EDT 2024 Tue Nov 26 11:13:36 EST 2024 Tue Nov 19 21:28:58 EST 2024 Tue Nov 12 23:35:24 EST 2024 Wed Oct 30 12:29:21 EDT 2024 Sat Nov 02 12:14:03 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Adherence Infliximab Immune-mediated inflammatory diseases |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3961-9ff8f1ce41f5d3fbd7a7b02d31b842938bc38b174251581d233e66f0deda26a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11523816/ |
| PMID | 39472788 |
| PQID | 3126413626 |
| PQPubID | 44673 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a9d1e5260de6408e91612dd325d61723 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11523816 proquest_miscellaneous_3122634308 proquest_journals_3126413626 gale_infotracmisc_A814182622 gale_infotracacademiconefile_A814182622 crossref_primary_10_1186_s12876_024_03455_w pubmed_primary_39472788 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-10-29 |
| PublicationDateYYYYMMDD | 2024-10-29 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC gastroenterology |
| PublicationTitleAlternate | BMC Gastroenterol |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | 3455_CR4 W Chan (3455_CR3) 2017; 15 World Health Organization (3455_CR5) 2003 D Choquette (3455_CR17) 2015; 42 DI Jang (3455_CR2) 2021; 22 NUL Tavares (3455_CR13) 2016; 50 3455_CR9 3455_CR7 GS Haar (3455_CR14) 2021; 17 S Li (3455_CR18) 2023; 14 BJ Wentworth (3455_CR11) 2018; 24 A Lopez (3455_CR8) 2013; 19 MA Blum (3455_CR10) 2011; 33 L Martelli (3455_CR12) 2017; 18 L Lichtenstein (3455_CR16) 2015; 9 G Schett (3455_CR1) 2021; 385 RKS Gomes (3455_CR6) 2017; 5 AF Souza (3455_CR15) 2021; 19 JF Brandse (3455_CR19) 2017; 23 |
| References_xml | – volume: 19 start-page: 1528 year: 2013 ident: 3455_CR8 publication-title: Inflam Bowel Dis doi: 10.1097/MIB.0b013e31828132cb contributor: fullname: A Lopez – volume: 24 start-page: 2053 year: 2018 ident: 3455_CR11 publication-title: Inflam Bowel Dis doi: 10.1093/ibd/izy102 contributor: fullname: BJ Wentworth – volume: 18 start-page: 566 year: 2017 ident: 3455_CR12 publication-title: J Dig Dis doi: 10.1111/1751-2980.12539 contributor: fullname: L Martelli – volume: 17 start-page: 1420 year: 2021 ident: 3455_CR14 publication-title: Res Social Adm Pharm doi: 10.1016/j.sapharm.2020.10.011 contributor: fullname: GS Haar – ident: 3455_CR4 – volume: 14 start-page: 1185026 year: 2023 ident: 3455_CR18 publication-title: Front Pharmacol doi: 10.3389/fphar.2023.1185026 contributor: fullname: S Li – ident: 3455_CR9 – volume-title: Adherence in long-term therapies: evidence for actions year: 2003 ident: 3455_CR5 contributor: fullname: World Health Organization – volume: 9 start-page: 806 year: 2015 ident: 3455_CR16 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjv096 contributor: fullname: L Lichtenstein – ident: 3455_CR7 – volume: 15 start-page: 434 year: 2017 ident: 3455_CR3 publication-title: Intest Res doi: 10.5217/ir.2017.15.4.434 contributor: fullname: W Chan – volume: 5 start-page: 204 year: 2017 ident: 3455_CR6 publication-title: Rev Bras Reumatol doi: 10.1016/j.rbr.2016.05.003 contributor: fullname: RKS Gomes – volume: 50 start-page: 10s year: 2016 ident: 3455_CR13 publication-title: Public Health Mag contributor: fullname: NUL Tavares – volume: 385 start-page: 628 year: 2021 ident: 3455_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMra1909094 contributor: fullname: G Schett – volume: 33 start-page: 901 year: 2011 ident: 3455_CR10 publication-title: Clin Ther doi: 10.1016/j.clinthera.2011.06.001 contributor: fullname: MA Blum – volume: 19 start-page: 2312 year: 2021 ident: 3455_CR15 publication-title: Pharm Pract (Granada) doi: 10.18549/PharmPract.2021.2.2312 contributor: fullname: AF Souza – volume: 22 start-page: 2719 year: 2021 ident: 3455_CR2 publication-title: Int J Mol Sci doi: 10.3390/ijms22052719 contributor: fullname: DI Jang – volume: 23 start-page: 650 year: 2017 ident: 3455_CR19 publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000001043 contributor: fullname: JF Brandse – volume: 42 start-page: 1105 year: 2015 ident: 3455_CR17 publication-title: J Rheumatol doi: 10.3899/jrheum.140538 contributor: fullname: D Choquette |
| SSID | ssj0017823 |
| Score | 2.428513 |
| Snippet | Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment adherence... Background Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However,... BackgroundInfliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However, treatment... Abstract Background Infliximab therapy is effective in controlling symptoms and attaining clinical remission of immune-mediated inflammatory diseases. However,... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 384 |
| SubjectTerms | Adherence Adult Aged Analysis Brazil Care and treatment Chronic illnesses Cohort analysis Cohort Studies Crohns disease Diseases Dosage and administration Drug administration Drug dosages Drug therapy Female Gastrointestinal Agents - therapeutic use Health aspects Hospitals Humans Immune-mediated inflammatory diseases Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - drug therapy Inflammatory diseases Infliximab Infliximab - therapeutic use Male Medical records Medical research Medical treatment Medication Adherence - statistics & numerical data Medicine, Experimental Middle Aged Monoclonal antibodies Normal distribution Patient compliance Patients Psoriasis Psoriatic arthritis Questionnaires Referral and Consultation - statistics & numerical data Remission Remission Induction Rheumatoid arthritis Schedules Sociodemographics Tumor necrosis factor-α |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9QwDI5gD4gL4k1hQUFC4oCibZ5Nuc3CrvYCF_bALUqaVFuJ6aymM1rEP-BfY6edaisOXDhUquq0SmO7tmv7CyHvbNWqUHnBGt8YplrbsGAqw3jUcB5i0A3-cLv4Vn39bj-fIUzOvNUX1oSN8MDjwp34OvKkweuOyajSJnBnuIhRCh3R-I44n6U5BFNT_gDsnjy0yFhzMsBXuMJiW8VKqbRmNwszlNH6__4m3zJKy4LJWxbo_CF5MLmOdDVO-RG5k_rH5N6XKTn-hPxexauxeY_uNrTDdo-f3doHOheTw0U6AakOFP_A0g7bQxLL_SPge-a7_HqdU-90St4MFHtQqKd5SxKYGMUJpi0-7XTrf3U_PgIRd9rd7miGq31KLs_PLj9dsGmnBdbI2nBWt61teZMUb3WUbYiVr0IpouTBgsGSNjRwQPAC3pAGD1dImYxpgSfRC-PlM3LUb_r0glCjvAEW1xAlNqrCrKESlQ7W6Io3noeCfDisu7se8TRcjkOscSOXHHDJZS65m4KcImvmkYiFnS-AhLhJQty_JKQg75GxDjUWuAdCOTYewIQR-8qtLFcYZQlRkOPFSNC0Zkk-iIabNH1wkoNLyRHUpyBvZzLeidVrfdrs8xhhpJKlLcjzUZLmV5K1AhfSAsUuZGzxzktK311lHHBw5tHhMi__xyq9IvcF6geYZVEfk6Pddp9ek7tD3L_JqvUHTCsoNQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Adherence to infliximab treatment in patients with immune-mediated inflammatory diseases from a referral center in Brazil: a cohort study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39472788 https://www.proquest.com/docview/3126413626 https://www.proquest.com/docview/3122634308 https://pubmed.ncbi.nlm.nih.gov/PMC11523816 https://doaj.org/article/a9d1e5260de6408e91612dd325d61723 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbdHEIupe86TRcVCj0UZ1cPy3JvmzQhpaQUmkNvQi83hqw37IOU_oP-687I9jZLbz0YjCUZyTPjmdHMfCLkrS5r6UrLc2-9ymWtfe5UqXIWCrh3wRUeN9wuvpVfvuuPZwiTo4ZamJS0711z3N7Mj9vmOuVW3s79ZMgTm3y9PAUrBjWNmozICIzDwUfvYweg88RQHqPVZAV_4BITbWU-FbIo8rsDsi8qCYo7HbfyVxsl0P5_f833dNNu3uQ9RXT-iDzsLUg662b6mDyI7ROyf9nHyJ-S37Nw3dXw0fWCNlj18bOZW0e3OeXwkPZ4qiuKG7G0wSqRmKcyEjBB0yg7n6cIPO1jOCuKpSjU0nQyCUyM4gTjEt92srS_mpsP0IgH7i7XNKHWPiNX52dXpxd5f-BC7kWlWF7Vta6Zj5LVRRC1C6Ut3ZQHwZwGvSW083CBDwNGUQGGLhciKlVPQwyWKyuek7120caXhCppFVC6AmfRyxKDh5KXhdOqKJm3zGXk_fDdzW0Hq2GSO6KV6QhmgGAmEczcZeQESbPtiZDY6cFi-cP0jGFsFVgswD0LUcmpjmD3Mh6C4EVAK01k5B0S1qDgAvWAN7v6A5gwQmCZmWYSnS3OM3K00xMEzu82D6xheoFfGcHAsmSI7ZORN9tmHIlJbG1cbFIfroQUU52RFx0nbZc0MGRG9A6P7ax5twWkI8GBD9Jw-P9DX5EDjgICOplXR2RvvdzE12S0CpsxuBmfPo_TVsU4ydkfsZgsGQ |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZokUovvB-BAkZC4oDSjR9xHG7b0moR3QqJPXCz_AqN1M1W-1AR_4B_zdhJlkbcelhplbFXO5pvPDOZhxF6L4uKm0LT1GorUl5JmxpRiJS4HL4bZ3IbXrhNvhfnP-TnkzAmR_S9MLFo35r6sLmcHzb1RaytvJrbUV8nNvo2PQYvJlgaMdpBd0Fhs6yP0rvsAVg91jfISDFawRlchFJbnmaM53l6vY_2WMnBdMcLV_7Zozi2___D-YZ1GlZO3jBFpw9uy8RDdL9zPvG4pT9Cd3zzGO1Nu_T6E_Rn7C7a9j-8XuA6NIz8qufa4G05OjzE3SjWFQ7vcHEdGkx8GjtQwHuNu_R8HpP3uEv_rHDoYsEax0tNgCMcOPPL8GtHS_27vvwExHBX73KN48Dbp2h2ejI7nqTdXQ2pZaUgaVlVsiLWc1LljlXGFbowGXWMGAkmj0lj4QPhD_hTOfjIlDEvRJU57zQVmj1Du82i8S8QFlwLAEkJcablRcg7clrkRoq8IFYTk6CPvcDUVTuRQ8VIRgrVSlqBpFWUtLpO0FGQ6XZlmKYdHyyWP1UnDqVLR3wOkZ3zgmfSg8tMqHOM5i44eCxBHwIiVNB5EDvAum1dgD8cpmepsSQ8xGmUJuhgsBJ01Q7JPaZUd1asFCPglJIwFihB77bksDPUvzV-sYlrqGCcZTJBz1sIblnqkZwgOQDngOchBTAZJ4n3GHx5-61v0b3JbHqmzr6cf32F9mnQMjDttDxAu-vlxr9GOyu3eRMV9C8vwj_f |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZNCiGXvh9u01aFQg_FWethWc5t81hS2oRAc-hN6OXEkPUu-yCl_6D_uiPZ3sb01h4MxpKMh5nRzHhmPiH0QRYVN4WmqdVWpLySNjWiEClxOdwbZ3IbfridfivOv8vjkwCTc9D3wsSifWvq_eZmut_U17G2cj61o75ObHRxdgReTLA0YjR31WgL3QelzWgfqXcZBLB8rG-SkWK0hH24COW2PM0Yz_P0dhftsJKD-Y6HrvyxSRG6_-8N-o6FGlZP3jFHk4f_Q8gj9KBzQvG4nfMY3fPNE7Rz1qXZn6JfY3fdtgHi1QzXoXHkRz3VBm_K0uEh7iBZlzj8y8V1aDTxaexEAS82rtLTaUzi4y4NtMShmwVrHA83AapwoM4vwtsOF_pnfXMAg-HM3sUKR-DbZ-hycnJ5dJp2ZzaklpWCpGVVyYpYz0mVO1YZV-jCZNQxYiSYPiaNhQvCIPCrcvCVKWNeiCpz3mkqNHuOtptZ418iLLgWICwlxJuWFyH_yGmRGynyglhNTII-9UxT8xaZQ8WIRgrVclsBt1XktrpN0GHg62ZmQNWOD2aLK9WxROnSEZ9DhOe84Jn04DoT6hyjuQuOHkvQxyAVKug-sB7Eu21hgA8OKFpqLAkP8RqlCdobzASdtcPhXq5Ut2csFSPgnJIAD5Sg95vhsDLUwTV-to5zqGCcZTJBL1ox3JDUS3OC5EBABzQPR0AuI6J4L4ev_n3pO7RzcTxRXz-ff3mNdmlQNLDwtNxD26vF2r9BW0u3fht19Dcq2EJf |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adherence+to+infliximab+treatment+in+patients+with+immune-mediated+inflammatory+diseases+from+a+referral+center+in+Brazil%3A+a+cohort+study&rft.jtitle=BMC+gastroenterology&rft.au=Priscila+Moreira+Lauton&rft.au=Fernanda+Silva+Pereira&rft.au=Livia+Brito+Oliveira&rft.au=Alline+Mikaelle+Nunes+Wildemberg+Brauer&rft.date=2024-10-29&rft.pub=BioMed+Central&rft.eissn=1471-230X&rft.volume=24&rft.spage=1&rft_id=info:doi/10.1186%2Fs12876-024-03455-w |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-230X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-230X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-230X&client=summon |